21-04-2025
New Investigational Drug TB006 FDA – Approved For Compassionate Use
Naples, FL - April 21, 2025 - TB006, a new investigational drug, has been approved by the US Food and Drug Administration (FDA) for compassionate use and is currently being evaluated in a clinical trial for Alzheimer's disease. The FDA's compassionate use designation allows patients with serious or life-threatening conditions to access investigational treatments when no satisfactory alternatives are available.
TB006 is currently undergoing clinical trials to assess its safety and potential effects on inflammation and cognitive function in individuals diagnosed with Alzheimer's disease. According to clinical investigators involved in early-stage research, the drug has been administered to over 300 patients to date, with no adverse side effects reported.
Preliminary data from a placebo-controlled trial suggested that:
These findings are currently being further investigated through ongoing clinical studies. With Alzheimer's disease on the rise, this is very exciting news for those over age 65 and those with a history of dementia in their family.
Among the clinical sites authorized to provide TB006 under compassionate use is Brain Power Clinics, located in West Palm Beach, Florida. The clinic is led by Dr. Joshua Helman, a Harvard-trained physician with over a decade of experience focused on integrative approaches to cognitive decline. Known to patients as Dr. Josh, he currently administers TB006 under FDA protocols as part of a broader, individualized care model.
Dr. Helman works in partnership with Dr. Robert Love, Ph.D., a neuroscientist recognized for his contributions to the field of Alzheimer's prevention and brain health. Together, the team at Brain Power Clinics offers a multidisciplinary approach that combines investigational therapies like TB006 with behavioral coaching and lifestyle interventions designed to support cognitive function.
Participation in the compassionate use program is limited to individuals who meet specific eligibility criteria, which include age and diagnosis parameters in accordance with FDA and clinical trial guidelines.
To learn more about working with Dr. Josh in his medical clinic, please text 'Memory' to 561-725-3319 or visit
Disclaimer:
Media Contact
Company Name: Brain Power Clinics
Contact Person: Robert Love
Email: Send Email
Phone: 305-209-0853
Country: United States
Website:
Source: Brand Featured
